![]() |
||||
|
||||
![]() |
||||
|
![]() |
||
![]() |
Dear Reader Between now and the symposium’s start on October 17, the Foundation will be providing regular updates regarding speakers, topics, sponsors and more via this newsletter, special emails and press releases. We invite you to follow along via Facebook and Twitter. While the Foundation is abuzz with symposium planning, our work of advocating for collaboration and supporting research continues. In this newsletter, we announce the launch of our newest strategic initiative: Focused Ultrasound-mediated Targeted Drug Delivery (FUS-TDD). Now in its initial stages, FUS-TDD has begun developing a group of highly-influential core stakeholders. Ultimately, the initiative will foster collaborations to accelerate development of new, minimally-invasive alternatives to chemotherapy and similar treatments. On the research front, we share the results of preclinical experiments in prostate cancer treatment performed by one of our funded researchers, Lili Chen, Ph.D. We also welcome three leading researchers – Katherine Whittaker Ferrara, Ph.D., Graeme Houston, M.D. and Ernst Martin, M.D. – to our independent advisory committees. |
![]() |
|||
Preliminary program and speakers announced for 2nd International Symposium on MR-guided Focused Ultrasound | |||
![]() |
|
![]() |
|
![]() |
![]() |
|||
Symposium and FUSF news now posted on Facebook and Twitter | |||
![]() |
|
![]() |
|
![]() |
![]() |
|||
Chen reports MR-guided focused ultrasound has potential to boost efficacy of prostate cancer drug | |||
![]() |
|
![]() |
|
![]() |
![]() |
|||
Foundation welcomes new advisory committee members: Ferrara, Martin and Houston | |||
![]() |
|
![]() |
|
![]() |
![]() |
![]() |